Myriad Genetics executes a comprehensive digital transformation strategy by integrating cutting-edge technologies into its core precision medicine workflows. The company specifically transforms its genetic testing operations through advanced AI, scalable data platforms, and robust EMR integrations. This strategic approach focuses on enhancing the accuracy and accessibility of genetic insights for healthcare providers and patients alike.
These digital advancements create critical dependencies on system interoperability, data integrity, and automated process reliability. The transformation introduces challenges where genetic test ordering, genomic data analysis, and result delivery must function flawlessly across interconnected systems. This page analyzes Myriad Genetics' key digital transformation initiatives and highlights operational control points that present potential sales opportunities.
Myriad Genetics Snapshot
Headquarters: Salt Lake City, United States
Number of employees: approximately 2,700 employees
Public or private: Public
Business model: B2B
Website: http://www.myriad.com
Myriad Genetics ICP and Buying Roles
Myriad Genetics sells to large healthcare systems and specialized clinical practices that manage complex patient genomics data. The company targets healthcare organizations with established electronic medical record systems and sophisticated laboratory operations.
Who drives buying decisions
- Chief Information Officer (CIO) → Oversees enterprise-wide technology strategy and infrastructure investments.
- Head of Clinical Operations → Manages patient care workflows and diagnostic service delivery.
- Director of Laboratory Operations → Directs laboratory automation and data processing systems.
- Head of Health Informatics → Governs clinical data integration and analytics platforms.
Key Digital Transformation Initiatives at Myriad Genetics (At a Glance)
- Integrating AI into genomic variant classification pipelines
- Connecting EMR systems for test ordering and results delivery
- Automating laboratory processes with advanced robotics
- Establishing a scalable data sharing platform for research
- Applying Generative AI for healthcare document processing
Where Myriad Genetics’s Digital Transformation Creates Sales Opportunities
| Vendor Type | Where to Sell (DT Initiative + Challenge) | Buyer / Owner | Solution Approach |
|---|---|---|---|
| AI Model Validation Platforms | Integrating AI into genomic variant classification: AI model misclassifies certain genetic variants before clinical reporting. | Chief Medical Officer, Head of Bioinformatics | Validate AI model outputs against established clinical guidelines and ground truth data. |
| Applying Generative AI for healthcare document processing: Generative AI misclassifies patient documents for prior authorization processing. | Director of Revenue Cycle, Head of Patient Access | Detect inconsistencies between AI classification and document content for billing. | |
| Data Integration & Orchestration Platforms | Connecting EMR systems for test ordering and results delivery: Test orders fail to propagate from EMR to Myriad's lab information system. | Head of Health Informatics, VP of IT | Enforce consistent data exchange between EMR platforms and laboratory information systems. |
| Establishing a scalable data sharing platform: De-identified patient data fails to load consistently into the research registry. | VP of Data Science, Chief Technology Officer | Standardize data formats and ingestion protocols for disparate clinical datasets. | |
| Laboratory Automation & Control Systems | Automating laboratory processes with advanced robotics: Robotic systems generate sample misidentifications before sequencing analysis. | Director of Laboratory Operations, Head of R&D | Validate sample identity and chain of custody across automated liquid handling workstations. |
| Data Privacy & Governance Solutions | Establishing a scalable data sharing platform: Data access controls fail to segregate research user groups within the registry. | Chief Information Security Officer, Legal Counsel | Enforce granular access policies on de-identified patient genomic data. |
| Process Mining & Automation Platforms | Connecting EMR systems for test ordering and results delivery: Manual review is required for EMR test orders that lack complete patient demographics. | Head of Clinical Operations, Process Improvement Lead | Route incomplete test order forms for automated data enrichment or clinician follow-up. |
| Bioinformatics Pipeline Management | Integrating AI into genomic variant classification: Computational pipelines stall when large genomic datasets fail to process. | Director of Bioinformatics, VP of Engineering | Detect pipeline bottlenecks and resource contention in cloud-based genomic analysis environments. |
Identify when companies like Myriad Genetics are in-market for your solutions.
Spot buying signals, find the right prospects, enrich your data, and reach out with relevant messaging at the right time.
What makes this Myriad Genetics’s digital transformation unique
Myriad Genetics' digital transformation uniquely prioritizes the deep integration of genetic insights directly into clinical decision-making workflows. The company heavily depends on robust, secure data sharing across disparate healthcare systems to make personalized medicine actionable at scale. This approach demands a unique focus on validating AI-driven interpretations and maintaining stringent data governance standards, making its transformation more complex than typical enterprise IT overhauls.
Myriad Genetics’s Digital Transformation: Operational Breakdown
DT Initiative 1: Integrating AI into Genomic Variant Classification
What the company is doing
Myriad Genetics embeds artificial intelligence and machine learning models into its bioinformatics pipelines. This process improves the speed and accuracy of classifying genetic variants. It also enhances the prediction of cancer risk based on genomic data.
Who owns this
- Chief Technology Officer (CTO)
- VP of Research & Development
- Director of Bioinformatics Software Engineering
Where It Fails
- AI models misclassify certain genetic variants before final clinical reporting.
- Computational pipelines stall when large genomic datasets fail to process.
- Variant annotation discrepancies appear between AI outputs and expert-curated databases.
Talk track
Noticed Myriad Genetics is integrating AI into its genomic variant classification. Been looking at how some precision medicine teams are validating AI model outputs against established clinical guidelines instead of manual review, can share what’s working if useful.
DT Initiative 2: EMR/EHR System Integration for Test Ordering and Results
What the company is doing
Myriad Genetics connects its genetic testing services with major Electronic Medical Record (EMR) and Electronic Health Record (EHR) platforms. This integration creates seamless workflows for healthcare providers to order genetic tests. It also delivers test results directly within their daily clinical systems.
Who owns this
- Head of Clinical Integrations
- Director of Health Informatics
- VP of Sales & Marketing
Where It Fails
- Test orders fail to propagate from EMR to Myriad's laboratory information system.
- Patient demographic data does not synchronize accurately between EMR and Myriad’s order entry portal.
- Genetic test results do not display correctly in provider EMR interfaces.
Talk track
Saw Myriad Genetics is connecting EMR systems for test ordering and results delivery. Been looking at how some healthcare organizations are enforcing consistent data exchange between EMRs and lab systems instead of managing data manually, happy to share what we’re seeing.
DT Initiative 3: Advanced Laboratory Automation
What the company is doing
Myriad Genetics modernizes its laboratory facilities with advanced robotics and instrumentation. This transformation aims to increase sample throughput and reduce reliance on manual processes. It also improves overall operational efficiency.
Who owns this
- Director of Laboratory Operations
- Head of R&D Engineering
- VP of Manufacturing
Where It Fails
- Robotic systems generate sample misidentifications before sequencing analysis.
- Automated liquid handlers dispense incorrect reagent volumes during assay preparation.
- Instrument calibration failures create inaccurate measurement data for genetic analysis.
Talk track
Looks like Myriad Genetics is automating laboratory processes with advanced robotics. Been seeing teams validate sample identity and chain of custody across automated workstations instead of manual checks, can share what’s working if useful.
DT Initiative 4: Establishing Scalable Data Sharing and a Treatment Registry
What the company is doing
Myriad Genetics partners with DNAnexus to create a scalable, cloud-based platform for bioinformatics data analysis. The company also launched the Myriad Collaborative Research Registry (MCRR). This registry shares large-scale genomic and clinical data for research purposes.
Who owns this
- VP of Data Science
- Chief Technology Officer (CTO)
- Head of Research Collaborations
Where It Fails
- De-identified patient data fails to load consistently into the research registry.
- Data access controls fail to segregate research user groups within the registry.
- Genomic data harmonization tools create inconsistencies across diverse patient datasets.
Talk track
Noticed Myriad Genetics is establishing a scalable data sharing platform for research. Been looking at how some genomics companies are standardizing data formats and ingestion protocols for disparate clinical datasets instead of cleaning data manually, happy to share what we’re seeing.
DT Initiative 5: Applying Generative AI for Healthcare Document Processing
What the company is doing
Myriad Genetics implements Generative AI to automate the classification and information extraction from healthcare documents. This initiative focuses specifically on prior authorization workflows. It aims to reduce manual effort and accelerate document processing.
Who owns this
- Director of Revenue Cycle Management
- Head of Patient Access Services
- VP of Information Technology
Where It Fails
- Generative AI misclassifies patient documents for prior authorization processing.
- Extracted key information (e.g., patient ID, insurance details) contains errors from unstructured document layouts.
- Prior authorization requests stall when the AI system fails to identify required forms.
Talk track
Saw Myriad Genetics is applying Generative AI for healthcare document processing. Been looking at how some revenue cycle teams are detecting inconsistencies between AI classification and document content for billing instead of manual validation, can share what’s working if useful.
Who Should Target Myriad Genetics Right Now
This account is relevant for:
- AI model governance and validation platforms
- Healthcare data integration and interoperability solutions
- Laboratory information management systems (LIMS) with automation control
- Cloud-based bioinformatics data platforms
- Generative AI solutions for intelligent document processing
- Data privacy and access management platforms
Not a fit for:
- Basic website builders with no integration capabilities
- Standalone marketing tools without system connectivity
- Products designed for small, low-complexity teams
When Myriad Genetics Is Worth Prioritizing
Prioritize if:
- You sell tools for AI model validation and performance monitoring in clinical diagnostics.
- You sell solutions that enforce consistent data exchange between EMR and laboratory systems.
- You sell platforms that validate sample identity and process integrity in automated labs.
- You sell tools for genomic data governance and research registry access management.
- You sell Generative AI solutions that detect errors in automated document classification.
Deprioritize if:
- Your solution does not address any of the breakdowns above.
- Your product is limited to basic functionality with no integration capabilities.
- Your offering is not built for multi-team or multi-system environments within healthcare.
Who Can Sell to Myriad Genetics Right Now
AI Model Validation Platforms
Crescendo AI - This company offers AI validation platforms that ensure machine learning models perform reliably and ethically.
Why they are relevant: Myriad's AI models misclassify certain genetic variants before clinical reporting. Crescendo AI can validate the accuracy of these AI model outputs, ensuring consistent and correct variant classification for patient care decisions.
Fiddler AI - This company provides an AI observability platform that helps organizations monitor, explain, and improve their AI models.
Why they are relevant: Genomic variant classification pipelines stall when AI models generate inaccurate predictions. Fiddler AI can detect performance degradation in Myriad's AI models, allowing for timely adjustments and preventing errors in genetic analysis.
Healthcare Data Integration Platforms
Rhapsody - This company offers an interoperability platform that connects healthcare applications and systems, enabling seamless data exchange.
Why they are relevant: Test orders fail to propagate from EMR to Myriad's lab information system. Rhapsody can enforce consistent and reliable data transfer, ensuring that genetic test orders move efficiently between Epic and Myriad's internal systems.
InterSystems - This company provides data management and integration solutions specifically designed for complex healthcare environments.
Why they are relevant: Patient demographic data does not synchronize accurately between EMR and Myriad’s order entry portal. InterSystems can standardize and validate patient data across connected systems, preventing discrepancies that cause workflow delays.
Laboratory Automation Software
Thermo Fisher Scientific (Momentum Automation Software) - This company offers software solutions that control and manage laboratory automation workflows and instruments.
Why they are relevant: Robotic systems generate sample misidentifications before sequencing analysis in Myriad's automated labs. Thermo Fisher's software can validate sample tracking and chain of custody across automated workstations, ensuring correct sample processing.
Beckman Coulter (Biomek Software) - This company provides software for liquid handlers and laboratory automation platforms, enabling precise control over experimental protocols.
Why they are relevant: Automated liquid handlers dispense incorrect reagent volumes during assay preparation. Beckman Coulter's software can enforce precise control over liquid dispensing, preventing errors that impact genetic test accuracy.
Genomic Data Governance Platforms
DNAnexus - This company offers a cloud-based platform for secure, scalable bioinformatics data analysis and management.
Why they are relevant: De-identified patient data fails to load consistently into Myriad's research registry. DNAnexus provides robust data ingestion and harmonization capabilities, ensuring all genomic data is reliably integrated for research.
Databricks (Unity Catalog) - This company provides a unified governance solution for data and AI, helping manage access and security for large datasets.
Why they are relevant: Data access controls fail to segregate research user groups within Myriad's data registry. Databricks Unity Catalog can enforce granular permissions and audit data access, ensuring compliance with data privacy regulations.
Final Take
Myriad Genetics is significantly scaling its precision medicine capabilities through advanced AI and extensive EMR integrations. Breakdowns are visible in AI model validation, seamless data flow between clinical systems and labs, and robust data governance within research registries. This account is a strong fit for sellers offering solutions that address these specific operational failures, enabling more accurate genomic insights and efficient healthcare delivery.
Identify buying signals from digital transformation at your target companies and find those already in-market.
Find the right contacts and use tailored messages to reach out with context.